4DMedical Ltd (ASX: 4DX) shares are rocketing on Wednesday morning.
In early trade, the ASX 300 stock is up a massive 38% to a record-high of $6.40.
Image source: Getty Images
Why is this ASX 300 stock rising today?
Investors have been buying the respiratory imaging technology company's shares following the release of a big announcement this morning.
According to the release, 4DMedical's CT:VQ technology has been deployed at the Mayo Clinic in the United States.
The release reveals that the Mayo Clinic, which is widely regarded as one of the world's leading hospitals, has entered into an agreement to use CT:VQ for ventilation and perfusion analysis.
The deployment will initially focus on integrating the technology into clinical workflows and allowing clinicians to evaluate its capabilities across a range of use cases.
Management highlights that the Mayo Clinic's adoption represents one of the most significant endorsements of its technology to date.
Building strong commercial momentum
The ASX 300 stock notes that it has achieved six major deployments for CT:VQ within approximately seven months of receiving FDA clearance in September 2025.
The others are Stanford, Cleveland Clinic, UC San Diego Health, University of Chicago Medicine, and the University of Miami.
This rapid adoption highlights growing demand for its technology, which offers advantages such as eliminating the need for radioisotopes and contrast agents, while providing high-resolution imaging and integration into existing CT workflows.
While the initial agreement with Mayo Clinic is not financially material, the company emphasised its strategic importance. Management believes that as clinicians gain confidence in the technology, the hospital could become a key reference site, supporting broader commercial adoption.
'A landmark moment'
The ASX 300 stock's managing director and CEO, Andreas Fouras, described the deployment as a landmark moment for the company. He said:
Mayo Clinic is, unquestionably, one of the most respected healthcare institutions in the world. Their decision to deploy CT:VQ is a landmark moment for 4DMedical and a powerful testament to the clinical significance of our technology. In just seven months since FDA clearance we have established CT:VQ at six of America's leading AMCs: Stanford, University of Miami, Cleveland Clinic, UC San Diego Health, University of Chicago Medicine, and now Mayo Clinic. No other technology in our space has achieved this level of clinical adoption in such a short timeframe.
Mayo's deployment is uniquely significant. When the world's number one hospital chooses to use your technology, it sends the strongest possible signal to the entire U.S. healthcare market about the clinical value and readiness of CT:VQ.
Fouras believes this leaves the company well-placed for the future. He concludes:
Combined with our existing network of elite AMC reference sites, and the Philips partnership, we are building an unassailable platform for CT:VQ adoption. CT:VQ continues to accelerate. Our sales pipeline has never looked stronger, and I look forward to sharing further progress soon.
